Company intelligence / Profile preview

VDyne

Maple Grove, Minnesota, United Statesvdyne.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The VDyne Valve System is an investigational, minimally invasive transcatheter device for treating tricuspid regurgitation. Early feasibility studies have shown successful implantation in high-risk patients with promising 30-day outcomes. The device is fully retrievable prior to final deployment, allowing assessment before release. Further clinical studies are ongoing to determine its long-term efficacy and safety[1][2][5].

Therapeutic areas: Cardiovascular
Modalities: Device (Transcatheter heart valve system)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

VDyne Valve System

Phase 1

Indications: Tricuspid regurgitation

Partnerships

Jean Boulle Group (major investor/strategic partner)

Beyond the preview

Go deeper on VDyne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDyne.

Explore the full profile